Vivo Bio Tech Ltd
NSE: BSE: 511509
₹27.03
(-0.62%)
Wed, 04 Mar 2026, 00:30 pm
Market Cap599.81M
PE Ratio11.67
Dividend0
Distribution Services
Medical Distributors
24.5KVivo Bio Tech Analysis
dividend
- Unable to evaluate Vivo Bio Tech's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Vivo Bio Tech's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Vivo Bio Tech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Vivo Bio Tech is profitable, therefore cash runway is not a concern.
- Vivo Bio Tech is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (26.3%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 1x debt.
- Vivo Bio Tech's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has increased over the past 5 years (65.7% vs 72.5% today).
- Interest payments on debt are not well covered by earnings (EBIT is 1.6x annual interest expense, ideally 3x coverage).
- Vivo Bio Tech's level of debt (72.5%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Vivo Bio Tech board of directors is about average.
- Kalyan's remuneration is lower than average for companies of similar size in India.
- Kalyan's compensation has been consistent with company performance over the past year, both up more than 20%.
- The average tenure for the Vivo Bio Tech management team is less than 2 years, this suggests a new team.
misc
- Vivo Bio Tech is not covered by any analysts.
- Vivo Bio Tech has significant price volatility in the past 3 months.
past
- Vivo Bio Tech's year on year earnings growth rate has been positive over the past 5 years.
- Vivo Bio Tech used its assets more efficiently than the IN Life Sciences industry average last year based on Return on Assets.
- Vivo Bio Tech has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Vivo Bio Tech's 1-year earnings growth is negative, it can't be compared to the 5-year average.
- Vivo Bio Tech has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Vivo Bio Tech's 1-year earnings growth is negative, it can't be compared to the IN Life Sciences industry average.
value
- Vivo Bio Tech is good value based on earnings compared to the IN Life Sciences industry average.
- Vivo Bio Tech is overvalued based on assets compared to the IN Life Sciences industry average.
- Vivo Bio Tech is overvalued based on earnings compared to the India market.
- 511509 underperformed the Life Sciences industry which returned 36.1% over the past year.
- 511509 underperformed the Market in India which returned -14.5% over the past year.
- BSE:511509 is up 1.3% underperforming the Life Sciences industry which returned 2.6% over the past month.
- BSE:511509 is up 1.3% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800